Cedar Health Research, a Texas-based clinical trial network focused on underserved patients, and Texas Native Health, a Dallas nonprofit serving American Indian and Alaska Native communities, announced on Wednesday that they have opened a new embedded Cedar Health Research site within Texas Native Health.
Established in 2023, the collaborative partnership aims to expand access to clinical research for Native American patients, a population that has historically been underrepresented in clinical trials.
The integrated site allows patients to participate in studies within their trusted care setting, reducing barriers such as travel, limited culturally informed study designs, and longstanding underrepresentation in clinical data.
Initially, the site will support studies addressing conditions disproportionately affecting Native American populations, such as cardiometabolic diseases. Native Americans are 36% more likely than the general US population to have diabetes, and approximately 50% of Native American adults are obese.
Cedar Health Research opens new embedded research site within Texas Native Health
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Alvotech reaches global settlement over aflibercept biosimilar patents
MedPal AI announces approval to supply Eli Lilly medicines in UK
Hanmi Pharmaceutical signs distribution agreement with Laboratorios Sanfer in Mexico
Viking Therapeutics publishes Phase 2 data showing up to 14.7% weight loss with VK2735
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
GSK wins European Commission approval for Shingrix prefilled syringe
Abbott launches Libre Assist for in-the-moment food decisions
RedHill advances RHB-102 across GI indications
FDA grants priority review for Sanofi's Tzield in young children with stage 2 type 1 diabetes
Samsung Bioepis begins direct commercialisation of BYOOVIZ in Europe
Diamyd Medical agrees accelerated efficacy readout in ongoing Phase 3 type 1 diabetes trial